FIRST AMENDMENT TO LICENSE AGREEMENT Sample Clauses

FIRST AMENDMENT TO LICENSE AGREEMENT. This First Amendment Agreement dated 11 November 2016 (the “Amendment”) to the Collaboration and License Agreement dated 26 August 2016 (the “Agreement”) is between MedImmune Limited, a company incorporated in England whose registered office is Xxxxxxxx Xxxxxxxx, Xxxxxx Xxxx, Xxxxxxxxx, XX00 0XX, XX (“Licensor”); AbMed Corporation a Delaware corporation with its principal place of business at 000 Xxxxxxxxx Xxxxx, Xxxxx 000, Xxxxx, Xxxx Xxxxxx, Delaware 19904 (“Company”); and AbPro Corporation, a Delaware corporation with its principal place of business at 00 Xxxxxxxx Xxxx Drive, Woburn, Massachusetts 01801 (“AbPro”).

FIRST AMENDMENT TO LICENSE AGREEMENT. This First Amendment to License Agreement (this “Amendment”) is dated as of the 22nd day of October, 2003, by and between Xxxxxx Laboratories, an Illinois corporation (“Abbott”) and Empire Pharmaceuticals, Inc., a Delaware corporation (“Empire”).

FIRST AMENDMENT TO LICENSE AGREEMENT. This First Amendment to License Agreement (this “ First Amendment”) dated as of this 13th day of December, 2002 (the “Amendment Effective Date”) is made by and between the parties listed below and amends the License Agreement (the “Original Agreement”) between such parties made the 30th day of September, 2000: FLIP CHIP TECHNOLOGIES, L.L.C. ) a Delaware limited liability company, ) (referred to as “FCT”) having a principal place of business at ) 3000 X. Xxxxxxxxxx Xxxxxx ) Pxxxxxx, Xxxxxxx 00000, XXX ) ) and ) ) CALIFORNIA MICRO DEVICES CORPORATION ) a California corporation ) (referred to as “CMD”) having a principal place of business at ) 400 Xxxxx XxXxxxxx Xxxx. ) Mxxxxxxx, Xxxxxxxxxx 00000 )

FIRST AMENDMENT TO LICENSE AGREEMENT. This First Amendment to the License Agreement (as defined below) effective as of June 28, 2013 (this “Amendment”), is made by and between AmpliPhi Biosciences, Inc., successor in interest to Targeted Genetics, Inc., having a principal place of business at 0000 Xxxxxx Xxxx, Suite 300, Glen Allen, VA 23060 (“AmpliPhi”) and uniQure Biopharma B.V., formerly known as Amsterdam Molecular Therapeutics B.V., a Dutch limited liability company having a principal place of business at Xxxxxxxxxxxx 00, 0000 XX Xxxxxxxxx, Xxx Xxxxxxxxxxx (“uniQure”) and amends the License Agreement dated December 5, 2006 by and between AmpliPhi and uniQure (the “Agreement” or “License Agreement”).

FIRST AMENDMENT TO LICENSE AGREEMENT. This FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is entered into this 28th day of October, 2022 (the “Effective Date”) by and between NWALP TPOP Property Owner LLC, a Delaware limited liability company (“Licensor”), and Upstream Bio, Inc., a Delaware corporation (“Licensee”).

FIRST AMENDMENT TO LICENSE AGREEMENT. We refer to the License Agreement between Roxro Pharma LLC and Recordati SA Chemical and Pharmaceutical Company whose Effective Date was 23 November 2000 (the 'License").

FIRST AMENDMENT TO LICENSE AGREEMENT. This FIRST AMENDMENT TO LICENSE AGREEMENT ("Amendment") is made and entered into as of the 7 day of January, 2011, by and between FSP 000 XXXX XXXXXX XXXXX LLC, a Delaware limited liability company ("Licensor"), and GROUPON INC., a Delaware corporation ("Licensee").

FIRST AMENDMENT TO LICENSE AGREEMENT. This First Amendment (“First Amendment”) to the License Agreement (as defined below) is made and entered into as of this 28th day of September, 2009 (“First Amendment to License Agreement Effective Date”) BETWEEN:

FIRST AMENDMENT TO LICENSE AGREEMENT. This is the First Amendment to the January 1, 1995 License Agreement between Genzyme Corporation (“GENZYME”) and Mount Sinai School of Medicine of the City University of New York (“MSSM”). This Amendment shall be effective as of October 7, 2003.

FIRST AMENDMENT TO LICENSE AGREEMENT. This First Amendment to License Agreement (the “First Amendment”) is made effective this 15th day of April 2008, by and between Anesiva, Inc. a company organized and existing pursuant to the laws of Delaware, USA and having a principal place of business at 000 Xxxxxxx Xxxxxxxxx, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000 XXX (“Anesiva”) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., a company subject to the direction and coordination of Sigma-Tau Finanziaria S.p.A., organized and existing under the laws of Italy and having its registered offices in Rome, 47 Xxxxx Xxxxxxxxxxx, 00000, Xxxxx (“Sigma-Tau” and together with Anesiva the “Parties”).